Clinical Trial Update: Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of ixazomib to prevent recurrent or late acute and chronic graft-versus-host disease after allogeneic stem cell transplantation has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoid Hematologic Malignancy
• Myeloid Hematologic Malignancy

Drugs mentioned

• ixazomib (ixazomib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Myeloid Hematologic Malignancy, Lymphoid Hematologic Malignancy | Phase 2 | Status: COMPLETED | Results posted: 2022-09-27